148 related articles for article (PubMed ID: 31619739)
1. Author Correction: Inhibition of casein kinase 1δ/εimproves cognitive-affective behavior and reduces amyloid load in the APP-PS1 mouse model of Alzheimer's disease.
Sundaram S; Nagaraj S; Mahoney H; Portugues A; Li W; Millsaps K; Faulkner J; Yunus A; Burns C; Bloom C; Said M; Pinto L; Azam S; Flores M; Henriksen A; Gamsby J; Gulick D
Sci Rep; 2019 Oct; 9(1):15167. PubMed ID: 31619739
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of casein kinase 1δ/εimproves cognitive-affective behavior and reduces amyloid load in the APP-PS1 mouse model of Alzheimer's disease.
Sundaram S; Nagaraj S; Mahoney H; Portugues A; Li W; Millsaps K; Faulkner J; Yunus A; Burns C; Bloom C; Said M; Pinto L; Azam S; Flores M; Henriksen A; Gamsby J; Gulick D
Sci Rep; 2019 Sep; 9(1):13743. PubMed ID: 31551449
[TBL] [Abstract][Full Text] [Related]
3. Effects of accelerated senescence on learning and memory, locomotion and anxiety-like behavior in APP/PS1 mouse model of Alzheimer's disease.
Lok K; Zhao H; Zhang C; He N; Shen H; Wang Z; Zhao W; Yin M
J Neurol Sci; 2013 Dec; 335(1-2):145-54. PubMed ID: 24095271
[TBL] [Abstract][Full Text] [Related]
4. Author Correction: Hybrid PET/MRI enables high-spatial resolution, quantitative imaging of amyloid plaques in an Alzheimer's disease mouse model.
Frost GR; Longo V; Li T; Jonas LA; Judenhofer M; Cherry S; Koutcher J; Lekaye C; Zanzonico P; Li YM
Sci Rep; 2020 Aug; 10(1):13826. PubMed ID: 32778663
[TBL] [Abstract][Full Text] [Related]
5. Long-term treadmill exercise inhibits the progression of Alzheimer's disease-like neuropathology in the hippocampus of APP/PS1 transgenic mice.
Liu HL; Zhao G; Zhang H; Shi LD
Behav Brain Res; 2013 Nov; 256():261-72. PubMed ID: 23968591
[TBL] [Abstract][Full Text] [Related]
6. An early dysregulation of FAK and MEK/ERK signaling pathways precedes the β-amyloid deposition in the olfactory bulb of APP/PS1 mouse model of Alzheimer's disease.
Lachén-Montes M; González-Morales A; de Morentin XM; Pérez-Valderrama E; Ausín K; Zelaya MV; Serna A; Aso E; Ferrer I; Fernández-Irigoyen J; Santamaría E
J Proteomics; 2016 Oct; 148():149-58. PubMed ID: 27498392
[TBL] [Abstract][Full Text] [Related]
7. The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease.
Collins JM; King AE; Woodhouse A; Kirkcaldie MT; Vickers JC
Exp Neurol; 2015 May; 267():219-29. PubMed ID: 25747037
[TBL] [Abstract][Full Text] [Related]
8. Amyloid and tau pathology of familial Alzheimer's disease APP/PS1 mouse model in a senescence phenotype background (SAMP8).
Porquet D; Andrés-Benito P; Griñán-Ferré C; Camins A; Ferrer I; Canudas AM; Del Valle J; Pallàs M
Age (Dordr); 2015 Feb; 37(1):9747. PubMed ID: 25663420
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the APP/PS1 mouse model of Alzheimer's disease in senescence accelerated background.
Lok K; Zhao H; Shen H; Wang Z; Gao X; Zhao W; Yin M
Neurosci Lett; 2013 Dec; 557 Pt B():84-9. PubMed ID: 24176881
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.
Hansen HH; Fabricius K; Barkholt P; Kongsbak-Wismann P; Schlumberger C; Jelsing J; Terwel D; Termont A; Pyke C; Knudsen LB; Vrang N
PLoS One; 2016; 11(7):e0158205. PubMed ID: 27421117
[TBL] [Abstract][Full Text] [Related]
11. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
McClean PL; Hölscher C
Neuropharmacology; 2014 Jan; 76 Pt A():57-67. PubMed ID: 23973293
[TBL] [Abstract][Full Text] [Related]
12. Traumatic Brain Injury Increases the Expression of Nos1, Aβ Clearance, and Epileptogenesis in APP/PS1 Mouse Model of Alzheimer's Disease.
Miszczuk D; Dębski KJ; Tanila H; Lukasiuk K; Pitkänen A
Mol Neurobiol; 2016 Dec; 53(10):7010-7027. PubMed ID: 26671618
[TBL] [Abstract][Full Text] [Related]
13. The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer's disease.
Duffy AM; Hölscher C
Neuroscience; 2013 Jan; 228():294-300. PubMed ID: 23103794
[TBL] [Abstract][Full Text] [Related]
14. Cerebral inoculation of human A53T α-synuclein reduces spatial memory decline and amyloid-β aggregation in APP/PS1 transgenic mice of Alzheimer's disease.
Hao YN; Lu QX; Zhai YH; Wang HY; Wu MN; Hu MM; Yang B; Wang ZJ; Wu ZW; Qi JS
Brain Res Bull; 2018 Oct; 143():116-122. PubMed ID: 30366065
[TBL] [Abstract][Full Text] [Related]
15. Author Correction: C/EBPβ regulates delta-secretase expression and mediates pathogenesis in mouse models of Alzheimer's disease.
Wang ZH; Gong K; Liu X; Zhang Z; Sun X; Wei ZZ; Yu SP; Manfredsson FP; Sandoval IM; Johnson PF; Jia J; Wang JZ; Ye K
Nat Commun; 2019 Nov; 10(1):5452. PubMed ID: 31772180
[TBL] [Abstract][Full Text] [Related]
16. HDAC3 negatively regulates spatial memory in a mouse model of Alzheimer's disease.
Zhu X; Wang S; Yu L; Jin J; Ye X; Liu Y; Xu Y
Aging Cell; 2017 Oct; 16(5):1073-1082. PubMed ID: 28771976
[TBL] [Abstract][Full Text] [Related]
17. Seizure susceptibility in the APP/PS1 mouse model of Alzheimer's disease and relationship with amyloid β plaques.
Reyes-Marin KE; Nuñez A
Brain Res; 2017 Dec; 1677():93-100. PubMed ID: 28963050
[TBL] [Abstract][Full Text] [Related]
18. Cholinergic degeneration is associated with increased plaque deposition and cognitive impairment in APPswe/PS1dE9 mice.
Laursen B; Mørk A; Plath N; Kristiansen U; Bastlund JF
Behav Brain Res; 2013 Mar; 240():146-52. PubMed ID: 23178660
[TBL] [Abstract][Full Text] [Related]
19. EGb761 improves cognitive function and regulates inflammatory responses in the APP/PS1 mouse.
Wan W; Zhang C; Danielsen M; Li Q; Chen W; Chan Y; Li Y
Exp Gerontol; 2016 Aug; 81():92-100. PubMed ID: 27220811
[TBL] [Abstract][Full Text] [Related]
20. Author Correction: Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease.
Zhou Y; Song WM; Andhey PS; Swain A; Levy T; Miller KR; Poliani PL; Cominelli M; Grover S; Gilfillan S; Cella M; Ulland TK; Zaitsev K; Miyashita A; Ikeuchi T; Sainouchi M; Kakita A; Bennett DA; Schneider JA; Nichols MR; Beausoleil SA; Ulrich JD; Holtzman DM; Artyomov MN; Colonna M
Nat Med; 2020 Jun; 26(6):981. PubMed ID: 32409732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
